Chantal Tasset, PhD

Galapagos NV
Mechelen, Belgium

Project Leader Development

Presentation(s):

• 0653: In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): No financial relationships with ineligible companies to disclose